Literature DB >> 28796877

Conjunctival Bacteria Flora of Glaucoma Patients During Long-Term Administration of Prostaglandin Analog Drops.

Shinichiro Ohtani1,2, Kimiya Shimizu3, Ryohei Nejima1,2, Fumie Kagaya1, Makoto Aihara4, Takuya Iwasaki1, Nobuyuki Shoji2, Kazunori Miyata1.   

Abstract

Purpose: To investigate the effects of the long-term use of prostaglandin analogs for glaucoma treatment on the indigenous flora of the conjunctiva.
Methods: Bacterial isolates were collected from the conjunctival sacs of 68 patients at Miyata Eye Hospital from February to September 2014, who had been receiving continuous monotherapy with prostaglandin analogs for glaucoma for at least 1 year. Minimum inhibitory concentrations of levofloxacin, gatifloxacin, moxifloxacin, cefmenoxime, tobramycin, chloramphenicol, and erythromycin against the isolates were measured to determine susceptibility.
Results: The positive culture rate in all cases was 90.5% (57/63 eyes), and a total of 79 bacterial strains were isolated. The isolated bacteria included aerobic gram-positive cocci (8% Staphylococcus aureus and 41% Staphylococcus epidermidis), coagulase-negative staphylococci (5%), Streptococcus spp. (1%), Corynebacterium spp. (4%), gram-negative bacteria (4%), and the facultative anaerobe Propionibacterium acnes (33%). The positive culture rates for patients using 0.005% latanoprost (Xa group) and 0.004% travoprost (Tz group) were 88.9% and 92.6%, respectively, with no statistically significant difference in the composition of isolated bacteria between groups. Methicillin-resistant S. epidermidis (MRSE) was significantly more frequently isolated in the Xa group. The antimicrobial susceptibility rates of S. epidermidis were significantly lower in the Xa group for levofloxacin, gatifloxacin, moxifloxacin, and tobramycin. Conclusions: The indigenous flora may be affected by the long-term use of prostaglandin analogs. The higher incidence of MRSE in the Xa group should be considered during the long-term, continuous administration of eye drops, such as in glaucoma treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28796877     DOI: 10.1167/iovs.16-20853

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  10 in total

Review 1.  The microbiome and ophthalmic disease.

Authors:  Adam D Baim; Asadolah Movahedan; Asim V Farooq; Dimitra Skondra
Journal:  Exp Biol Med (Maywood)       Date:  2018-11-21

2.  Differences in the eyelid and buccal microbiome of glaucoma patients receiving long-term administration of prostaglandin analog drops.

Authors:  Su-Ho Lim; Jong Hoon Shin; Ji-Woong Lee; Young Lee; Je Hyun Seo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-05-07       Impact factor: 3.117

Review 3.  Ocular surface flora and prophylactic antibiotics for cataract surgery in the age of antimicrobial resistance.

Authors:  Takuya Iwasaki; Ryohei Nejima; Kazunori Miyata
Journal:  Jpn J Ophthalmol       Date:  2022-01-10       Impact factor: 2.447

4.  Bacteriological profiles and drug susceptibility of Streptococcus isolated from conjunctival sac of healthy children.

Authors:  Ruili Ke; Min Zhang; Qin Zhou; Yunfei Yang; Ruifen Shen; Huipin Huang; Xiangrong Zhang
Journal:  BMC Pediatr       Date:  2020-06-22       Impact factor: 2.125

5.  Pseudomonas keratitis complicated with spontaneous expulsive suprachoroidal hemorrhage: A case report.

Authors:  Ju-Wen Yang
Journal:  Medicine (Baltimore)       Date:  2022-02-11       Impact factor: 1.817

Review 6.  Ocular surface microbiota: Ophthalmic infectious disease and probiotics.

Authors:  Ming-Cheng Chiang; Edward Chern
Journal:  Front Microbiol       Date:  2022-08-19       Impact factor: 6.064

7.  Topical Glaucoma Therapy Is Associated With Alterations of the Ocular Surface Microbiome.

Authors:  Chih-Chiun J Chang; Karina Somohano; Christine Zemsky; Anne-Catrin Uhlemann; Jeffrey Liebmann; George A Cioffi; Lama A Al-Aswad; Susan V Lynch; Bryan J Winn
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

8.  Is it time for a moratorium on the use of benzalkonium chloride in eyedrops?

Authors:  Luca D'andrea; Marina Montemagni; Giuseppe Celenza; Roberto Iorio; Ciro Costagliola
Journal:  Br J Clin Pharmacol       Date:  2022-05-08       Impact factor: 3.716

9.  Effect of clinical parameters on the ocular surface microbiome in children and adults.

Authors:  Kara M Cavuoto; Roberto Mendez; Darlene Miller; Anat Galor; Santanu Banerjee
Journal:  Clin Ophthalmol       Date:  2018-07-02

10.  Benzalkonium Chloride Resistance in Staphylococcus epidermidis on the Ocular Surface of Glaucoma Patients Under Long-Term Administration of Eye Drops.

Authors:  Jinhee Lee; Takuya Iwasaki; Shinichiro Ohtani; Hidehito Matsui; Ryohei Nejima; Yosai Mori; Fumie Kagaya; Akiko Yagi; Akiko Yoshimura; Hideaki Hanaki; Makoto Aihara; Kazunori Miyata
Journal:  Transl Vis Sci Technol       Date:  2020-07-07       Impact factor: 3.283

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.